• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , June 30

AUROBINDO Pharma Ltd (APL) has obtained the compliance of the World Health Organisation (WHO) for its facility manufacturing anti-retroviral (ARV) drugs. The WHO approval is an important prerequisite for several global sourcing programmes.

In a press release here on Thursday, the company said the WHO inspected its unit-III facility and found it to be in compliance with the WHO GMP standards.

According to Aurobindo Pharma, WHO has initiated the project along with UNICEF, UNAIDS and UNFPA in the context of increasing the access and improving the affordability of HIV/AIDS-related care and treatment.

The WHO had invited expression of interest from manufacturers of pharmaceutical products in respect of the provision of drugs for the management HIV-related diseases.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Grasim sells 7.39 pc stake in Century Enka

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line